International producer of flexible and specialist packaging the Clondalkin Group has acquired Keller Crescent, reportedly the largest independently owned producer of folding cartons, labels, inserts, outserts and other packaging components servicing the North American pharmaceutical and healthcare markets.
The purchase price has not been disclosed. However, Clondalkin says the acquisition expands its “prominent position” in pharmaceutical packaging supply to one of market leadership in North America.
Keller Crescent joins other dedicated Clondalkin pharmaceutical supply companies, including Pharmagraphics, which operates four complementary production facilities in North Carolina, Connecticut and Puerto Rico. In Europe, Clondalkin supplies the pharma sector from Pharmagraphics Guy in Cork and Kenilworth Products in Dublin; it also has operations in the UK, Poland, the Netherlands and Germany supplying the pharmaceutical and healthcare markets.
Headquartered in Evansville, Indiana, Keller Crescent operates three main production plants in Evansville, Indianapolis, Indiana and Charlotte, North Carolina. Clondalkin says the company is the “long-standing and preferred supplier” to several leading global pharmaceutical companies, with secondary packaging manufacture for pharma and healthcare customers accounting for over 90% of its sales.
Clondalkin Group ceo Norbert McDermott says: “Keller Crescent is deservedly the strongest independent brand name in the North American pharmaceutical market and is synonymous with top quality service and supply of packaging components to the pharmaceutical markets.
“In terms of locations, technology, product capability and customers supplied, Keller Crescent complements our Pharmagraphics operations extremely well. Coupled with our European capabilities, Clondalkin now has the presence and experience to service this truly global market. In total we have 10 dedicated pharmaceutical packaging production locations in the US, Ireland, Poland and Puerto Rico, and we also deliver the pharmaceutical standard as a specialisation from several more of our production sites.
“Completing the Keller Crescent acquisition is a very important step in enhancing Clondalkin’s product portfolio, where our focus is on high value added products, as it increases our pharmaceutical, healthcare, cosmetics/toiletries and personal care activities to almost 25% of our annual group sales.”